This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat expectations in the second quarter propelled by the momentum in the HIV franchise.
5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates
by Zacks Equity Research
Biotech industry experiences a turnaround in June. Here are five stocks which are expected to beat expectation in Q2.
Implied Volatility Surging for Acorda (ACOR) Stock Options
by Zacks Equity Research
Acorda (ACOR) needs investors to pay close attention to the stock based on moves in the options market lately.
Acorda Therapeutics (ACOR) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares rise nearly 9% on the day.
Acorda (ACOR) Up 13.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acorda (ACOR) Q1 Earnings Miss Estimates, Sales Down Y/Y
by Zacks Equity Research
Acorda's (ACOR) earnings and revenues lag estimates in Q1. The company reiterates its 2018 outlook for the key drug Ampyra.
New Strong Sell Stocks for April 18th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Acorda Files Parkinson's Drug Marketing Application in EU
by Zacks Equity Research
Acorda Therapeutics (ACOR) is seeking approval of its Parkinson's disease candidate, Inbrija, in Europe for the treatment of symptoms of OFF periods.
FDA Accepts Acorda's NDA for Parkinson's Disease Candidate
by Zacks Equity Research
FDA accepts Acorda's (ACOR) new drug application (NDA) for its parkinson's disease candidate, Inbrija and it also set an action date of Oct 5, 2018.
Acorda (ACOR) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Acorda (ACOR) misses on earnings in Q4 but beats on revenue estimates. The company's key drug Ampyra witnesses an increase in sales both year over year and sequentially.
Options Traders Expect Huge Moves in Acorda Therapeutics (ACOR) Stock
by Zacks Equity Research
Acorda Therapeutics (ACOR) needs investors to pay close attention to the stock based on moves in the options market lately.
Alkermes Submits NDA for Depression Candidate to the FDA
by Zacks Equity Research
Alkermes (ALKS) files a new drug application to the FDA for ALKS 5461's effective use in the adjunctive treatment of major depressive disorder (MDD).
Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8%
by Zacks Equity Research
Acorda Therapeutics (ACOR) was a big mover last session, as the company saw its shares nearly 9% on the day amid huge volumes.
Acorda's Shares Down on Disappointing Ampyra View for 2018
by Zacks Equity Research
Acorda (ACOR) announces preliminary sales numbers of its key multiple sclerosis drug, Ampyra, for Q4. The company's net sales expectations are higher year over year.
Surging Earnings Estimates Signal Good News for Acorda Therapeutics (ACOR)
by Zacks Equity Research
Acorda Therapeutics (ACOR) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision in addition to having decent short-term momentum.
Acorda Resubmits NDA for Parkinson's Disease Candidate Inbrija
by Zacks Equity Research
Acorda (ACOR) resubmits new drug application for its late stage pipeline candidate, Inbrija to the FDA.
Parkinson's Space in Focus as Acorda Stops Tozadenant Trial
by Zacks Equity Research
Acorda scraps development of a key Parkinson's disease candidate, tozadenant. With the discontinuation, investors' focus once again shifts to the Parkinson's space.
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
by Arpita Dutt
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Acorda Stock Up Despite Phase III Trial on Tozadenant Stops
by Zacks Equity Research
Acorda (ACOR) decides to suspend the phase III study on tozadenant based on new data obtained from the trial, spotting comprise with patient's safety.
Acorda Reports Death in Parkinson's Trials, Stock Down 40%
by Zacks Equity Research
Acorda's (ACOR) shares slump significantly after the company complains of safety issues related to a late-stage study on tozadenant, a lead Parkinson's disease candidate.
Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y
by Zacks Equity Research
Acorda's (ACOR) performance in Q3 misses earnings and revenue estimates. However, the company's key drug Ampyra witnessed increase in sales year over year and inched up sequentially.
Company News For Nov 1, 2017
by Zacks Equity Research
Companies in the news are: PFE, UA,AET, ACOR
Allergan (AGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q3 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
by Zacks Equity Research
Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi
AstraZeneca and Takeda Ink Deal to Develop Parkinson's Drug
by Zacks Equity Research
AstraZeneca (AZN) and Takeda Pharmaceutical Company entered into an agreement to jointly develop and commercialize MEDI1341 for the potential treatment of Parkinson's disease.